Clinical data | |
---|---|
Trade names | Sufrexal |
AHFS/Drugs.com | International Drug Names |
ATC code | C02KD01 (WHO) QD03AX90 (WHO) |
Identifiers | |
|
|
Synonyms | R41468; R-41468; R-41,468 |
CAS Number | 74050-98-9 |
PubChem (CID) | 3822 |
IUPHAR/BPS | 88 |
ChemSpider | 3690 |
UNII | 97F9DE4CT4 |
KEGG | D02363 |
ChEBI | CHEBI:6123 |
ChEMBL | CHEMBL51 |
ECHA InfoCard | 100.070.598 |
Chemical and physical data | |
Formula | C22H22FN3O3 |
Molar mass | 395.43 g/mol |
3D model (Jmol) | Interactive image |
|
|
|
|
(what is this?) |
Ketanserin (INN, USAN, BAN) (brand name Sufrexal; former developmental code name R41468) is a drug used clinically as an antihypertensive agent and in scientific research to study the serotonin system; specifically, the 5-HT2 receptor family. It was discovered at Janssen Pharmaceutica in 1980.
Ketanserin is classified as an antihypertensive by the World Health Organization and the National Institute of Health.
It has been used to reverse pulmonary hypertension caused by protamine (which in turn was administered to reverse the effects of heparin overdose).
The reduction in hypertension is not associated with reflex tachycardia.
It has been used in cardiac surgery.
With tritium (3H) radioactively labeled ketanserin is used as a radioligand for serotonin 5-HT2 receptors, e.g. in receptor binding assays and autoradiography. This radio-labeling has enabled the study of serotonin 5-HT2A receptor distribution in the human brain.
An autoradiography study of the human cerebellum has found an increasing binding of 3H-ketanserin with age (from below 50 femtomol per milligram tissue at around 30 years og age to over 100 above 75 years). The same research team found no significant correlation with age in their homogenate binding study.